Patents by Inventor James J. Mulé

James J. Mulé has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNE GENE SIGNATURES IN MUSCLE INVASIVE BLADDER CANCER
    Publication number: 20230323468
    Abstract: This invention relates to methods for selecting a treatment and optionally treating subjects with muscle-invasive bladder cancer based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
    Type: Application
    Filed: August 27, 2021
    Publication date: October 12, 2023
    Inventors: Roger Li, James J. Mulé, Anders Erik Berglund
  • TUMOR-INFILTRATING LYMPHOCYTES WITH ENHANCED TUMOR REACTIVITY
    Publication number: 20230086675
    Abstract: Disclosed are compositions and methods for targeted treatment of infections and cancers expressing cancers. In particular, tumor infiltrating lymphocytes (TILs) are identified that can be used with adoptive cell transfer to target, penetrate, and kill solid tumor masses. Therefore, also disclosed are methods of providing an immunotherapy in a subject with an infection or cancer that involves adoptive transfer of the disclosed TILs.
    Type: Application
    Filed: February 26, 2021
    Publication date: March 23, 2023
    Inventor: James J. Mulé
  • Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
    Publication number: 20220340874
    Abstract: Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.
    Type: Application
    Filed: June 28, 2022
    Publication date: October 27, 2022
    Inventors: Amod A. Sarnaik, Jeffrey S. Weber, Shari Pilon-Thomas, Laszlo G. Radvanyi, Jessica Ann Chacon, James J. Mule, MacLean S. Hall
  • Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
    Patent number: 11401506
    Abstract: Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: August 2, 2022
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Board nf Regents The Inivercitvof Texas Cvctom
    Inventors: Amod A. Sarnaik, Jeffrey S. Weber, Shari Pilon-Thomas, Laszlo G. Radvanyi, Jessica Ann Chacon, James J. Mule, MacLean S. Hall
  • Immune Gene Signatures in Cancer
    Publication number: 20210381061
    Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
    Type: Application
    Filed: May 25, 2021
    Publication date: December 9, 2021
    Inventors: James J. Mulé, Domenico Coppola, Timothy J. Yeatman, Audrey Loboda, Michael V. Nebozhyn
  • Immune Gene Signatures in Cancer
    Publication number: 20200399706
    Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
    Type: Application
    Filed: May 6, 2020
    Publication date: December 24, 2020
    Inventors: James J. Mulé, Domenico Coppola, Timothy J. Yeatman, Audrey Loboda, Michael V. Nebozhyn
  • Immune gene signatures in treating breast cancer
    Patent number: 10648040
    Abstract: This invention relates to methods for treating subjects with breast cancer, based on tumor expression levels of chemokines.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: May 12, 2020
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: James J. Mulé, Domenico Coppola, Timothy J. Yeatman, Audrey Loboda, Michael V. Nebozhyn
  • Immune gene signatures in urothelial carcinoma (UC)
    Patent number: 10583183
    Abstract: This invention relates to methods for treating subjects with bladder cancer, such as urothelial carcinoma, based on mRNA expression levels of chemokines.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: March 10, 2020
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Anthony M. Magliocco, James J. Mulé, Anders Erik Berglund
  • Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
    Publication number: 20200032209
    Abstract: Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.
    Type: Application
    Filed: December 20, 2018
    Publication date: January 30, 2020
    Inventors: Amod A. Sarnaik, Jeffrey S. Weber, Shari Pilon-Thomas, Laszlo G. Radvanyi, Jessica Ann Chacon, James J. Mule, MacLean S. Hall
  • Immune Gene Signatures in Cancer
    Publication number: 20190010556
    Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
    Type: Application
    Filed: July 6, 2018
    Publication date: January 10, 2019
    Inventors: James J. Mulé, Domenico Coppola, Timothy J. Yeatman, Audrey Loboda, Michael V. Nebozhyn
  • Immune gene signatures in cancer
    Patent number: 10041129
    Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: August 7, 2018
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: James J. Mulé, Domenico Coppola, Timothy J. Yeatman, Andrey Loboda, Michael V. Nebozhyn
  • Immune Gene Signatures in Urothelial Carcinoma (UC)
    Publication number: 20170175199
    Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
    Type: Application
    Filed: April 10, 2015
    Publication date: June 22, 2017
    Inventors: Anthony M. MAGLIOCCO, James J. MULE, Anders Erik BERGLUND
  • Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
    Publication number: 20170044496
    Abstract: Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.
    Type: Application
    Filed: April 10, 2015
    Publication date: February 16, 2017
    Inventors: Amod A. Sarnaik, Jeffrey S. Weber, Shari Pilon-Thomas, Laszlo G. Radvanyi, Jessica Ann Chacon, James J. Mule'
  • Immune Gene Signatures in Cancer
    Publication number: 20160326599
    Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
    Type: Application
    Filed: June 2, 2016
    Publication date: November 10, 2016
    Inventors: James J. Mulé, Domenico Coppola, Timothy J. Yeatman, Andrey Loboda, Michael V. Nebozhyn
  • Immune gene signatures in cancer
    Patent number: 9404926
    Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: August 2, 2016
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: James J. Mulé, Domenico Coppola, Timothy J. Yeatman, Andrey Loboda, Michael V. Nebozhyn
  • Creating bioengineered lymph nodes
    Patent number: 9234175
    Abstract: The invention provides compositions and methods of treating various conditions, including tumors, with compositions comprising dendritic cells expressing exogenous chemokines.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: January 12, 2016
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventor: James J. Mule
  • METHODS AND APPARATUSES USING MOLECULAR FINGERPRINTS TO PROVIDE TARGETED THERAPEUTIC STRATEGIES
    Publication number: 20150154368
    Abstract: Methods and apparatuses using molecular fingerprints to provide targeted therapeutic strategies are disclosed herein. The molecular fingerprints can be maintained and dynamically updated based on newly discovered and relevant information to improve individualized care.
    Type: Application
    Filed: July 25, 2013
    Publication date: June 4, 2015
    Inventors: Johnathan M. Lancaster, James J. Mulé
  • Enhanced dendritic cells for cancer immunotherapy
    Patent number: 8597946
    Abstract: Described herein are methods of cancer immunotherapy, particularly methods of preparing a population of enhanced dendritic cells and methods of treating cancer using the enhanced dendritic cells.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: December 3, 2013
    Assignees: H. Lee Moffitt Caner Center and Research Institute, Inc., The Regents of the University of Michigan
    Inventors: James J. Mule, Shari A. Pilon-Thomas, Norimasa Matsushita, Annabelle Grolleau-Julius
  • CHEMOKINE GENE-MODIFIED CELLS FOR CANCER IMMUNOTHERAPY
    Publication number: 20130251752
    Abstract: Described herein are methods of cancer immunotherapy, particularly compositions comprising genetically-modified cells that express macrophage colony stimulating factor (GM-CSF), CD40 ligand (CD40L), and chemokine C-C motif ligand 21 (CCL21), wherein the population of cells comprises bystander cells and target cancer cells, and methods of making these compositions and treating cancer using these compositions.
    Type: Application
    Filed: May 13, 2013
    Publication date: September 26, 2013
    Applicants: University of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Scott J. Antonia, James J. Mule
  • Immune Gene Signatures in Cancer
    Publication number: 20130034540
    Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
    Type: Application
    Filed: January 28, 2011
    Publication date: February 7, 2013
    Applicant: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: James J. Mulé, Domenico Coppola, Timothy J. Yeatman, Andrey Loboda, Michael V. Nebozhyn